Skip to main content

Nkarta, Inc.

NKTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001787400

No open-market purchases or sales by Nkarta, Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $167.9M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Nkarta, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of NKTX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders9789−8
Shares26.3M24.1M−2.17M (−8.2%)
Value$866.8M$764.7M−$102.1M (−11.8%)

New holders (16)

Institutions that held Nkarta, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to NKTX in Q2 2021
InstitutionSharesValue% of portfolio
International Biotechnology Trust PLC70,000$2.21M0.59%
Ergoteles LLC32,500$1.03M0.02%
HRT Financial LP31,762$1.01M0.01%
Los Angeles Capital Management LLC11,652$369.0K0.00%
Virtu Financial LLC10,782$342.0K0.03%
State Board of Administration of Florida Retirement System10,177$323.0K0.00%
Apollon Wealth Management, LLC8,000$254.0K0.05%
Principal Financial Group Inc7,525$238.0K0.00%
L & S Advisors Inc7,500$238.0K0.03%
Citadel Advisors LLC7,219$229.0K0.00%
ExodusPoint Capital Management, LP6,822$216.0K0.00%
Optiver Holding B.V.2,730$87.0K0.01%
Simplex Trading, LLC1,166$36.0K0.00%
IFP Advisors, Inc400$13.0K0.00%
Toth Financial Advisory Corp50$2.00K0.00%
Ellevest, Inc.4$00.00%

Sold out (24)

Institutions that held Nkarta, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.